CHEMED CORP Stock: price and directors' dealings · United States · SEC (Form 4)Follow the CHEMED CORP share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, CHEMED CORP has logged 198 public disclosures. Market capitalisation: €7.1bn. The latest transaction was reported on 24 August 2026 (Cession). Among the most active insiders: MCNAMARA KEVIN J. Every trade is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,196 of 29,063 companies
FCF yld 4.8%
Earn yld 3.9%
EV/EBITDA 16.4x
ROE 27%
Gross mgn 33%
Net mgn 10%
Debt/EBITDA 0.3x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
All Executives198 Thresholds0 Prospectus0 Other0
Declarations 198 total
▼ president and CEO · Executives · 21 Aug 2026
2,000 shares @ US$541.16 Capital Stock SEC:0001193125-26-362133:0
▼ executive vice president · Executives · 21 Aug 2026
1,000 shares @ US$541.04 Capital Stock SEC:0001193125-26-362146:0
◇ VP and Chief Legal Officer · Executives · 10 Aug 2026
6,786 shares @ US$445.35 0.042% mcap 31.2% of flow Capital Stock SEC:0001193125-26-342087:0
● VP and Chief Legal Officer · Executives · 10 Aug 2026
5,878 shares @ US$548.96 0.045% mcap 33.3% of flow Capital Stock SEC:0001193125-26-342087:1
◇ CEO - Vitas Healthcare · Executives · 5 Aug 2026
2,599 shares @ US$445.35 0.016% mcap 46.0% of flow Capital Stock SEC:0001193125-26-337649:0
● CEO - Vitas Healthcare · Executives · 5 Aug 2026
2,270 shares @ US$542.62 0.017% mcap 49.0% of flow Capital Stock SEC:0001193125-26-337649:1
◇ president and CEO · Executives · 31 Jul 2026
2,001 shares @ US$445.35 0.013% mcap 1.0% of flow Capital Stock SEC:0001193125-26-331690:0
● president and CEO · Executives · 31 Jul 2026
19,802 shares @ US$529.22 0.15% mcap 11.4% of flow Capital Stock SEC:0001193125-26-331690:1
▼ president and CEO · Executives · 3 Aug 2026
2,000 shares @ US$539.51 0.015% mcap 1.2% of flow Capital Stock SEC:0001193125-26-331690:2
▼ Director · Executives · 31 Jul 2026
190 shares @ US$532.00 0.0014% mcap 6.5% of flow Capital Stock SEC:0001193125-26-330302:0
▼ Director · Executives · 9 Jun 2026
1,347 shares Capital Stock SEC:0001193125-26-265474:0
▼ Director · Executives · 29 May 2026
500 shares @ US$437.83 0.0032% mcap 10.6% of flow Capital Stock SEC:0001193125-26-248086:0
▼ president and CEO · Executives · 27 Mar 2026
1,500 shares @ US$369.37 0.7% of flow Capital Stock SEC:0001193125-26-131183:0
▼ president and CEO · Executives · 12 Mar 2026
2,000 shares @ US$403.18 1.0% of flow Capital Stock SEC:0001193125-26-105545:0
◇ executive vice president · Executives · 13 Feb 2026
499 shares @ US$469.56 1.4% of flow Capital Stock SEC:0001193125-26-054949:0
◇ vice president · Executives · 13 Feb 2026
199 shares @ US$469.56 1.0% of flow Capital Stock SEC:0001193125-26-054877:0
◇ CEO - Vitas Healthcare · Executives · 13 Feb 2026
273 shares @ US$469.56 100.0% of flow Capital Stock SEC:0001193125-26-054514:0
◇ VP & Chief Financial Officer · Executives · 13 Feb 2026
413 shares @ US$469.56 1.4% of flow Capital Stock SEC:0001193125-26-054421:0
◇ president and CEO · Executives · 13 Feb 2026
2,714 shares @ US$469.56 1.6% of flow Capital Stock SEC:0001193125-26-054351:0
◇ VP and Chief Legal Officer · Executives · 13 Feb 2026
351 shares @ US$469.56 2.7% of flow Capital Stock SEC:0001193125-26-054242:0
● Director · Executives · 26 Dec 2025
463 shares 0Capital Stock SEC:0001193125-25-334117:0
▼ president and CEO · Executives · 24 Nov 2025
2,000 shares @ US$437.55 1.1% of flow Capital Stock SEC:0001193125-25-296515:0
● executive vice president · Executives · 19 Nov 2025
60 shares 0Capital Stock SEC:0001193125-25-288067:0
▼ president and CEO · Executives · 26 Sept 2025
3,000 shares @ US$461.28 1.8% of flow Capital Stock SEC:0001193125-25-222199:0
▼ Director · Executives · 9 Sept 2025
150 shares @ US$463.39 4.7% of flow Capital Stock SEC:0001230970-25-000005:0
25 of 198 declarations
Load more (173 remaining) 关于 CHEMED CORP Chemed Corp. (NYSE: CHE) 是一家在美国纽约证券交易所上市的公司,公司总部位于俄亥俄州辛辛那提。该集团可被理解为一家围绕 VITAS Healthcare 和 Roto-Rooter 建立的双平台服务公司。Chemed 于 1970 年在特拉华州注册成立,是 W.R. Grace & Co. 的子公司,于 1971 年继承了 Special Products Group,并于 1982 年独立。这段历史很重要:Chemed 仍然是一家以资本配置为导向的控股公司,拥有分散的运营业务,并且两个部门之间的重叠有限。
VITAS 是该公司的医疗保健平台,也是美国最大的临终关怀和生命末期护理提供商之一。其模式侧重于非治愈性护理,旨在通过医疗、护理、社会和精神服务改善患者舒适度并支持家庭。Roto-Rooter 是第二个支柱,是北美领先的管道、排水清洁、水清理和相关紧急修复服务品牌。这两项业务赋予 Chemed 独特的形象:一个受监管、对报销敏感的医疗保健特许经营权,与一个更以消费者和物业服务为导向的运营相结合,后者往往受益于经常性的紧急需求。
从竞争角度来看,VITAS 在一个运营执行、转诊网络、人员配备和报销管理至关重要的市场中受益于规模。Roto-Rooter 在住宅、商业和市政客户中享有强大的品牌认知度和广泛的服务范围。总的来说,这些业务在美国境内提供了地域多元化,并暴露于不同的需求驱动因素,尽管该公司仍主要在国内运营。Chemed 的收益可能受到临终关怀中医疗保险上限机制、劳动力成本和服务组合的影响,而 Roto-Rooter 的业绩则更多地与服务量、天气模式、住房相关活动和定价挂钩。
最近的发展强调了对股东回报的关注。Chemed 于 2026 年 4 月 23 日公布了 2026 年第一季度业绩,其投资者关系页面显示在 2026 年 5 月持续参与医疗保健会议。最值得注意的是,在 2026 年 5 月 13 日,董事会批准额外拨款 300 million 美元用于股票回购,这加强了管理层向股东返还多余资本的意愿。对于投资者而言,Chemed 提供了一种独特的组合,即防御性医疗保健现金生成和以服务为主导的运营杠杆,使其成为一个差异化的美国纽约证券交易所上市公司,而非纯粹的医疗保健股票。